Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Yuneva, T. Fan, Thaddeus Allen, R. Higashi, D. Ferraris, T. Tsukamoto, J. Matés, F. Alonso, Chunmei Wang, Youngho Seo, Xin Chen, J. Bishop (2012)
The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.Cell metabolism, 15 2
T. O'Brien, J. Oeh, Yang Xiao, Xiaorong Liang, Alexander Vanderbilt, Ann Qin, Lulu Yang, Leslie Lee, J. Ly, Ely Cosino, J. Lacap, A. Ogasawara, Simon Williams, M. Nannini, B. Liederer, P. Jackson, P. Dragovich, D. Sampath (2013)
Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.Neoplasia, 15 12
SEER) Program (www.seer.cancer.gov). National Cancer Institute, DCCPS, Surveillance Research Program, released
R. Gatenby, R. Gillies (2004)
Why do cancers have high aerobic glycolysis?Nature Reviews Cancer, 4
(2013)
Seminal study outlining non-canonical glutamine metabolic pathway in pancreatic cancer for the first time
M. Beg, Xiumei Huang, Molly Silvers, D. Gerber, J. Bolluyt, V. Sarode, F. Fattah, R. Deberardinis, M. Merritt, Xian-Jin Xie, R. Leff, D. Laheru, D. Boothman (2017)
Using a novel NQO1 bioactivatable drug, beta‐lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancerJournal of Surgical Oncology, 116
S. Jeong, Sunsook Hwang, Kyungsoo Park, Seungyeon Yang, R. Seong (2016)
Enhanced mitochondrial glutamine anaplerosis suppresses pancreatic cancer growth through autophagy inhibitionScientific Reports, 6
M. Hasmann, I. Schemainda (2003)
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.Cancer research, 63 21
O. Warburg (1956)
[Origin of cancer cells].Oncologia, 9 2
E. Bey, Melissa Bentle, Kathryn Reinicke, Ying Dong, Chin-Rang Yang, L. Girard, J. Minna, W. Bornmann, Jinming Gao, D. Boothman (2007)
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachoneProceedings of the National Academy of Sciences, 104
A. Alistar, B. Morris, R. Desnoyer, H. Klepin, K. Hosseinzadeh, C. Clark, A. Cameron, J. Leyendecker, R. D’Agostino, U. Topaloglu, L. Boteju, Asela Boteju, R. Shorr, Z. Zachar, P. Bingham, T. Ahmed, S. Crane, Riddhishkumar Shah, J. Migliano, T. Pardee, L. Miller, G. Hawkins, G. Jin, Wei Zhang, B. Pasche (2017)
A phase 1 study of first-in-class agent CPI-613 in combination with FOLFIRINOX for metastatic pancreatic cancerThe Lancet. Oncology, 18
Tzuling Cheng, J. Sudderth, Chendong Yang, A. Mullen, Eunsook Jin, J. Matés, R. Deberardinis (2011)
Pyruvate carboxylase is required for glutamine-independent growth of tumor cellsProceedings of the National Academy of Sciences, 108
G. Chakrabarti, Zachary Moore, Xiuquan Luo, Mariya Ilcheva, Aktar Ali, Mahesh Padanad, Yunyun Zhou, Yang Xie, S. Burma, P. Scaglioni, L. Cantley, R. Deberardinis, Alec Kimmelman, C. Lyssiotis, D. Boothman (2015)
Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachoneCancer & Metabolism, 3
R. Deberardinis, A. Mancuso, E. Daikhin, I. Nissim, M. Yudkoff, S. Wehrli, C. Thompson (2007)
Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesisProceedings of the National Academy of Sciences, 104
Shenghong Yang, Xiaoxu Wang, G. Contino, M. Liesa, Ergun Sahin, H. Ying, Alexandra Bause, Yinghua Li, J. Stommel, G. Dell’Antonio, J. Mautner, G. Tonon, M. Haigis, O. Shirihai, C. Doglioni, N. Bardeesy, Alec Kimmelman (2011)
Pancreatic cancers require autophagy for tumor growth.Genes & development, 25 7
Mette Jensen, K. Erichsen, C. Johnbeck, F. Björkling, J. Madsen, M. Bzorek, P. Jensen, L. Højgaard, M. Sehested, A. Kjær (2013)
[18F]FLT and [18F]FDG PET for Non-invasive Treatment Monitoring of the Nicotinamide Phosphoribosyltransferase Inhibitor APO866 in Human XenograftsPLoS ONE, 8
K. Holen, L. Saltz, E. Hollywood, K. Burk, A. Hanauske (2008)
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitorInvestigational New Drugs, 26
Ashley Solmonson, R. Deberardinis (2017)
Lipoic acid metabolism and mitochondrial redox regulationThe Journal of Biological Chemistry, 293
D. Gerber, A. Bisen, M. Beg, A. Frankel, Oluwatomilade Fatunde, F. Fattah, Y. Arriaga, J. Dowell, C. Meek, J. Bolluyt, V. Sarode, Xin Luo, Yang Xie, B. Schwartz, D. Boothman, R. Leff (2017)
Phase 1 study of ARQ 761, a β-lapachone analog that promotes NQO1-mediated programmed cancer cell necrosis.Journal of Clinical Oncology, 35
Molly Silvers, S. Deja, Naveen Singh, Robert Egnatchik, J. Sudderth, Xiuquan Luo, M. Beg, Shawn Burgess, R. Deberardinis, D. Boothman, M. Merritt (2017)
The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolismThe Journal of Biological Chemistry, 292
C. Chini, A. Guerrico, Verónica Nin, Juliana Camacho-Pereira, C. Escande, M. Barbosa, E. Chini (2013)
Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic TumorsClinical Cancer Research, 20
S. Colombo, M. Palacios-Callender, N. Frakich, Saul Carcamo, I. Kovács, Slavica Tudzarova, S. Moncada (2011)
Molecular basis for the differential use of glucose and glutamine in cell proliferation as revealed by synchronized HeLa cellsProceedings of the National Academy of Sciences, 108
A. Choo, Sang Kim, M. Heiden, S. Mahoney, Hieu Vu, Sang-Oh Yoon, L. Cantley, J. Blenis (2010)
Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply.Molecular cell, 38 4
Shawn Stuart, Alexandra Schauble, Sunita Gupta, A. Kennedy, B. Keppler, P. Bingham, Z. Zachar (2014)
A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox processCancer & Metabolism, 2
(1930)
The metabolism of tumours: investigations from the Kaiser Wilhelm Institute for Biology, Berlin-Dahlem
Meghan Seltzer, Bryson Bennett, A. Joshi, P. Gao, A. Thomas, D. Ferraris, T. Tsukamoto, C. Rojas, B. Slusher, J. Rabinowitz, C. Dang, G. Riggins (2010)
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.Cancer research, 70 22
J. Son, C. Lyssiotis, H. Ying, Xiaoxu Wang, S. Hua, M. Ligorio, R. Perera, C. Ferrone, Edouard Mullarky, Ng Shyh‐Chang, Ya'an Kang, J. Fleming, N. Bardeesy, J. Asara, M. Haigis, R. DePinho, L. Cantley, Alec Kimmelman (2013)
Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathwayNature, 496
A. Nahimana, A. Attinger, D. Aubry, P. Greaney, C. Ireson, A. Thougaard, J. Tjørnelund, K. Dawson, M. Dupuis, M. Duchosal (2009)
The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.Blood, 113 14
Yang Xiao, Kristi Elkins, Jenni Durieux, Leslie Lee, J. Oeh, Lulu Yang, Xiaorong Liang, Chris DelNagro, Jarrod Tremayne, M. Kwong, B. Liederer, P. Jackson, L. Belmont, D. Sampath, T. O'Brien (2013)
Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618.Neoplasia, 15 10
Nida Awadallah, D. Dehn, R. Shah, S. Nash, Yang Chen, David Ross, J. Bentz, K. Shroyer (2007)
NQO1 Expression in Pancreatic Cancer and Its Potential Use as a BiomarkerApplied Immunohistochemistry & Molecular Morphology, 16
M. Rosenfeldt, J. O'prey, J. Morton, C. Nixon, G. Mackay, Agata Mrowinska, Amy Au, T. Rai, Liang Zheng, R. Ridgway, P. Adams, K. Anderson, E. Gottlieb, O. Sansom, K. Ryan (2013)
p53 status determines the role of autophagy in pancreatic tumour developmentNature, 504
C. Beadnell (1938)
Origin of CancerBritish Medical Journal, 1
Jian‐bin Wang, J. Erickson, R. Fuji, Sekar Ramachandran, P. Gao, Ramani Dinavahi, K. Wilson, A. Ambrosio, S. Dias, C. Dang, R. Cerione (2010)
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation.Cancer cell, 18 3
D. Hanahan, R. Weinberg (2011)
Hallmarks of Cancer: The Next GenerationCell, 144
S. Sener, A. Fremgen, H. Menck, D. Winchester (1999)
Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.Journal of the American College of Surgeons, 189 1
Purpose of Review Pancreatic adenocarcinoma is a leading cause of cancer mortality in western countries with a uniformly poor prognosis. Unfortunately, there has been little in the way of novel therapeutics for this malignancy over the last several decades. Derangements in metabolic circuitry favoring excess glycolysis are increasingly recognized as a key hallmark of cancer. Recent Findings The role of alterations in glutamine metabolism in pancreatic tumor progression has been elucidated in animal models and human cells lines, and there has been considerable interest in exploiting these aberrations for the treatment of pancreatic cancer. Other strategies targeting NQO1/GLS1 inhibition, NAD+ synthesis, and TCA cycle intermediates are being actively studied in the clinic. Summary Aberrant metabolism in pancreatic cancer poses a unique therapeutic strategy. We review preclinical and clinical studies looking to exploit alterations in the metabolic circuitry of pancreatic cancer. . . . . Keywords Pancreatic cancer Glutamine Anaplerosis NADPH-quinone oxidoreductase 1 ß-lapachone Abbreviations ROS Reactive oxygen species α-KG α-Ketoglutarate TCA Tricarboxylic acid cycle β-lap β-Lapchone BPTES Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2- yl)ethyl sulfide Introduction Gln Glutamine GlnI Glutamine synthase Pancreatic adenocarcinoma (PDAC) is a leading cause of Gls1 Glutaminase 1 cancer-related mortality in western countries. In the USA, Gls2 Glutaminase 2 there
Current Oncology Reports – Springer Journals
Published: May 11, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.